- Details
- Alicia Morgans is joined by Andrea Necchi in a conversation on the CheckMate 274 trial, the use of biomarkers in the adjuvant setting, and how they can be used to understand the effect of nivolumab. Necchi and colleagues performed an exploratory analysis to assess the association between disease-free survival (DFS) and biomarkers (continuous scale) and estimate treatment-effect hazard ratios for b...
|
- Details
- Alicia Morgans and Guru Sonpavde discuss the results of Cohort K of the EV-103 trial presented at the 2022 European Society for Medical Oncology (ESMO) Annual Congress. There remains a critical need for effective and tolerable first-line treatment options in locally advanced or metastatic urothelial cancer. In second and later-line settings, both EV and pembrolizumab have independently shown an ov...
|
- Details
- Jonathan Rosenberg joins Alicia Morgans to discuss long-term outcomes of enfortumab vedotin (EV) in patients with previously treated advanced urothelial carcinoma (UC) in the EV-301 trial. The EV-301 trial demonstrated improvements in progression-free and overall survival for patients with previously treated advanced UC who received EV compared to chemotherapy. In discussing how this updated analy...
|
- Details
- Jonathan Rosenberg discusses the promising results from Cohort K, a part of a multi-cohort phase 1B/2 study examining enfortumab in combination with other agents, notably pembrolizumab. The primary endpoint, objective response rate, indicates a 64.5% response with the combination treatment. This rate is significant compared to a 45% response observed with enfortumab monotherapy. Dr. Rosenberg also...
|
- Details
- In this conversation, Arlene Siefker-Radtke and Shilpa Gupta join Patrick Hensley to discuss the role of risk-stratified neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer who are undergoing radical cystectomy. Drs. Siefker-Radtke and Gupta explain how systemic chemotherapy can be very challenging for bladder cancer patients due to the long-term side effects it can cause, alo...
|
- Details
- Alicia Morgans speaks with Robert Jones about the ATLANTIS Trial, focusing on an embedded randomization that studied the efficacy of Cabozantinib in urothelial carcinoma patients post-chemotherapy. Dr. Jones explains that the ATLANTIS platform aims to explore precision medicine in urothelial cancer and includes an "all-comers" arm to ensure broader patient participation. Unfortunately, the study f...
|
- Details
- In this conversation with Alicia Morgans, Rafee Talukder and Petros Grivas share data that investigates comparing the outcomes in patients who received prior intravesical BCG, and those patients who progressed and then required immune checkpoint inhibitors, to see if prior BCG therapy had an effect on the response on immune checkpoint inhibitors. Their hypothesis was, that patients who received BC...
|
- Details
- Sam Chang and Robert Dreicer delve into the evolving landscape of adjuvant trials for urothelial carcinoma. Dr. Dreicer discusses three pivotal studies: IMvigor010, CheckMate 274, and AMBASSADOR, each exploring different drugs like atezolizumab, nivolumab, and pembrolizumab in high-risk patient populations. While IMvigor010 showed negative results, CheckMate 274 demonstrated a disease-free surviva...
|
- Details
- Ashish Kamat hosts Alexander Wyatt to discuss the role of circulating tumor DNA (ctDNA) in the clinical management of urothelial carcinoma, especially in metastatic cases. Dr. Wyatt highlights ctDNA's utility in cancer screening, residual disease detection, and therapy monitoring. Data indicates that higher levels of ctDNA often correlate with worse disease prognosis. The conversation also explore...
|
- Details
- Alicia Morgans interviews Simon Crabb about the ATLANTIS trial. This UK-based, investigator-led study focuses on the use of rucaparib in advanced urothelial carcinoma patients who have undergone first-line chemotherapy. The trial employs biomarker analyses to determine patient eligibility, specifically looking at DNA repair efficiency. The primary endpoint, progression-free survival, showed a sign...
|
